PKO Investment Management Joint Stock Co Makes New Investment in Johnson & Johnson (NYSE:JNJ)

PKO Investment Management Joint Stock Co acquired a new stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 24,000 shares of the company's stock, valued at approximately $3,471,000.

A number of other large investors also recently modified their holdings of the business. WealthTrak Capital Management LLC acquired a new position in shares of Johnson & Johnson in the fourth quarter worth about $26,000. Mountain Hill Investment Partners Corp. bought a new position in shares of Johnson & Johnson in the fourth quarter valued at about $29,000. Bay Harbor Wealth Management LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $32,000. Conquis Financial LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at approximately $33,000. Finally, Bernard Wealth Management Corp. acquired a new position in Johnson & Johnson during the 4th quarter worth approximately $36,000. 69.55% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on JNJ. Morgan Stanley increased their price objective on Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 16th. Benchmark raised Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $181.00 price target on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Raymond James lowered their price target on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a report on Monday, April 14th. Finally, Barclays decreased their price objective on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a report on Thursday, April 17th. Eleven investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $170.88.

Johnson & Johnson Stock Up 0.7%

Shares of NYSE:JNJ traded up $1.01 during trading hours on Thursday, reaching $153.44. The stock had a trading volume of 6,810,517 shares, compared to its average volume of 7,947,271. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The stock has a market capitalization of $369.19 billion, a price-to-earnings ratio of 23.07, a P/E/G ratio of 2.56 and a beta of 0.42. The firm's 50 day moving average is $154.63 and its 200-day moving average is $153.64.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be paid a dividend of $1.30 per share. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date is Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.39%. Johnson & Johnson's payout ratio is presently 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.